Yes Augment, the trial wont affect anything in regards to a sale of the Consumer Healthcare group. An aquisition probably wont have a huge effect either. You see these small pharma product acquisitions occur from these big companies and they hardly hit the share price at all. So often there is no impact on the market cap. All it might do is ease the acquisition path by showing longevity for a core asset or two. Its hard to judge if that would make buying it worthwhile or not.
Pfizer sell down of OTC assets, page-5
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.015(7.32%) |
Mkt cap ! $200.9M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 19.0¢ | $407.7K | 2.054M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 114775 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 21756 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| ALA (ASX) Chart |